
Eli Lilly and Company: updates and filings
Price
$1,351.12
November 19, 2026Market cap $1.27T
What Ploutos Investor adds for Eli Lilly and Company
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 29, 2026next Jan 29, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
August 2026
April 2026
February 2026
November 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Oct 29, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 29, 2026Results of operationsForm8-K
- Oct 19, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 16, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operationsForm8-K
- Jul 30, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- Jul 24, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 24, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 23, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 23, 2026Employee stock plan reportfor the period to Dec 31, 2025Form11-K
- Jun 2, 2026One of its securities removed from an exchange (usually a matured note)Form25-NSE
- May 20, 2026Other material eventsForm8-K
- May 11, 2026Conflict minerals reportFormSD
- May 7, 2026Shareholder voteForm8-K
- May 1, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 30, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 30, 2026Results of operationsForm8-K
- Apr 29, 2026Shareholder letter ahead of the meetingFormPX14A6G
- Apr 20, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 31, 2026FilingFormDFAN14A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 20, 2026Additional annual meeting materialFormDEFA14A
- Mar 20, 2026Annual meeting proxy statementFormDEF 14A
- Mar 6, 2026Preliminary proxy statementFormPRE 14A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Oct 29, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 29, 2026 | 8-K | Results of operations | Document |
| Oct 19, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 16, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations | Document |
| Jul 30, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| Jul 24, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 24, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 23, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 23, 2026 | 11-K | Employee stock plan reportfor the period to Dec 31, 2025 | Document |
| Jun 2, 2026 | 25-NSE | One of its securities removed from an exchange (usually a matured note) | Document |
| May 20, 2026 | 8-K | Other material events | Document |
| May 11, 2026 | SD | Conflict minerals report | Document |
| May 7, 2026 | 8-K | Shareholder vote | Document |
| May 1, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 30, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 30, 2026 | 8-K | Results of operations | Document |
| Apr 29, 2026 | PX14A6G | Shareholder letter ahead of the meeting | Document |
| Apr 20, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 31, 2026 | DFAN14A | Filing | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 20, 2026 | DEFA14A | Additional annual meeting material | Document |
| Mar 20, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 6, 2026 | PRE 14A | Preliminary proxy statement | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Feb 8, 1994: every report, 8-K, meeting and letter. Of its other filings (1,003 in all), the newest. Of its note and share prospectuses (424B, FWP), the newest 40 of 65.
The full analysis
What do Eli Lilly and Company's filings show?
The filings are where every one of Eli Lilly and Company's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.